Retatrutide is a synthetic peptide developed by Eli Lilly that acts as a triple agonist at GLP-1, GIP, and glucagon receptors simultaneously — a novel mechanism among incretin-based compounds that has generated…
🔬 Studied for: Weight-Management Research
💊 Also studied for: Metabolic-Pathway Research
🧪 Not FDA-approved — sold strictly for laboratory research
📈 No standardized human dosage established in published literature
Retatrutide is a synthetic peptide developed by Eli Lilly that acts as a triple agonist at GLP-1, GIP, and glucagon receptors simultaneously — a novel mechanism among incretin-based compounds that has generated substantial research and media interest in metabolic and obesity research.
By simultaneously activating three distinct incretin-family receptors — GLP-1, GIP, and glucagon receptors — Retatrutide is studied for combining appetite suppression (GLP-1/GIP) with increased energy expenditure via the glucagon receptor, a combination researchers have proposed may produce greater metabolic effects than single- or dual-agonist compounds.
These are effects Retatrutide has been studied for in available preclinical and early research — not claims about guaranteed outcomes.
Published Phase 2 clinical trial data has shown substantial body-weight reduction in trial participants, making Retatrutide one of the most closely watched investigational compounds in obesity-pharmacology research.
Beyond weight outcomes, researchers have studied Retatrutide's triple-agonist mechanism for its effects on markers of liver fat, blood glucose, and lipid metabolism in trial populations.
Doses used in published Phase 2 clinical trials are documented in that trial literature and are specific to those regulated study protocols; no FDA-approved commercial dosage exists for Retatrutide research material.
Compound X does not provide dosing recommendations. Retatrutide is sold for laboratory research use only and is not intended for human consumption.
Published clinical trial data for Retatrutide has reported gastrointestinal side effects (nausea, diarrhea, vomiting) consistent with other incretin-receptor agonists, along with the trial-specific safety monitoring associated with an investigational drug; it is not FDA-approved, and research-grade material sourced outside Eli Lilly's regulated trial supply chain has not undergone the same quality controls.
No. Retatrutide is not FDA-approved for any indication and is sold strictly as a research chemical, not a medication or dietary supplement.
Weight-Management Research — Published Phase 2 clinical trial data has shown substantial body-weight reduction in trial participants, making Retatrutide one of the most closely watched investigational compounds in obesity-pharmacology research.
In the US, UK, Canada and Australia, Retatrutide is generally sold labeled "for research use only, not for human consumption." It is not approved as a dietary supplement or medication in any of these countries.
Retatrutide clinical trial data is indexed on PubMed and ClinicalTrials.gov under "Retatrutide triple agonist obesity trial."
Compare current prices, purity testing claims and coupon codes across every vendor Compound X tracks.
New guides, vendor comparisons and compound breakdowns every week.